<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02376361</url>
  </required_header>
  <id_info>
    <org_study_id>20140235</org_study_id>
    <nct_id>NCT02376361</nct_id>
  </id_info>
  <brief_title>Hemodialysis Access Surveillance Evaluation Study</brief_title>
  <acronym>HASE</acronym>
  <official_title>Hemodialysis Access Surveillance Evaluation Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albany Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Transonic Systems Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Albany Medical College</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to learn if monitoring dialysis access blood flow during dialysis&#xD;
      treatment with a transonic machine (an ultrasound technique) will prevent (or reduce) the&#xD;
      development of dialysis access thrombosis (clotting).&#xD;
&#xD;
      Investigators would like to study if monitoring with a specific technique called ultrasound&#xD;
      dilution technique can help prevent problems with access when compared to what is the current&#xD;
      standard of care for patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodialysis Access Thrombosis Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evaluate the reduction of hemodialysis access thrombosis rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tunneled Hemodialysis Catheter Rate</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evaluate the reduction of tunneled hemodialysis catheter rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Tunneled Hemodialysis Catheter</measure>
    <time_frame>Up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hemodialysis Access Thrombectomy Procedures</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evaluate the reduction of hemodialysis access thrombectomy procedures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Hemodialysis Access Angiogram and Angioplasty Procedures</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Evaluate the reduction of hemodialysis access angiogram and angioplasty procedures</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">436</enrollment>
  <condition>Hemodialysis Access</condition>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>Surveillance Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group will receive standard monitoring (standard care).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transonic</intervention_name>
    <description>Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
    <arm_group_label>Surveillance Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic hemodialysis patients undergoing dialysis therapy via an upper extremity&#xD;
             arteriovenous access (arteriovenous fistula or an arteriovenous graft) will be&#xD;
             enrolled to have monthly surveillance flow measurement using Transonic system or&#xD;
             physical examination of the arteriovenous access by qualified person at least once a&#xD;
             month for a period of 2 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients requiring surgical intervention on the arteriovenous access.&#xD;
&#xD;
          -  History of access thrombosis (one or more access thrombosis of the current&#xD;
             arteriovenous access).&#xD;
&#xD;
          -  Patients with signs of access infection.&#xD;
&#xD;
          -  Patients with a malignancy.&#xD;
&#xD;
          -  Patients with life expectancy of less than six months.&#xD;
&#xD;
          -  Unable to understand the study.&#xD;
&#xD;
          -  Unable to sign the consent form.&#xD;
&#xD;
          -  Patients with psychiatric disorder.&#xD;
&#xD;
          -  Age less than 18 or greater than 80 years.&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Loay Salman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North America Research Institute</name>
      <address>
        <city>Azusa</city>
        <state>California</state>
        <zip>91702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2015</study_first_posted>
  <results_first_submitted>January 15, 2021</results_first_submitted>
  <results_first_submitted_qc>February 4, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albany Medical College</investigator_affiliation>
    <investigator_full_name>Loay Salman, MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Surveillance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 27, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT02376361/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Surveillance Group</title>
          <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>Control group will receive standard monitoring (standard care).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="207"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="171"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Surveillance Group</title>
          <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>Control group will receive standard monitoring (standard care).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="436"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="97"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.996" spread="11.855"/>
                    <measurement group_id="B2" value="61.826" spread="11.942"/>
                    <measurement group_id="B3" value="61.4" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="280"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                    <measurement group_id="B2" value="93"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemodialysis Access Thrombosis Rate</title>
        <description>Evaluate the reduction of hemodialysis access thrombosis rate</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surveillance Group</title>
            <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group will receive standard monitoring (standard care).</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodialysis Access Thrombosis Rate</title>
          <description>Evaluate the reduction of hemodialysis access thrombosis rate</description>
          <units>thrombotic events per patient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.122" lower_limit="0.081" upper_limit="0.177"/>
                    <measurement group_id="O2" value="0.227" lower_limit="0.167" upper_limit="0.302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tunneled Hemodialysis Catheter Rate</title>
        <description>Evaluate the reduction of tunneled hemodialysis catheter rate</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surveillance Group</title>
            <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group will receive standard monitoring (standard care).</description>
          </group>
        </group_list>
        <measure>
          <title>Tunneled Hemodialysis Catheter Rate</title>
          <description>Evaluate the reduction of tunneled hemodialysis catheter rate</description>
          <units>Events per patient</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.039" lower_limit="0.018" upper_limit="0.075"/>
                    <measurement group_id="O2" value="0.053" lower_limit="0.027" upper_limit="0.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Tunneled Hemodialysis Catheter</title>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surveillance Group</title>
            <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group will receive standard monitoring (standard care).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Tunneled Hemodialysis Catheter</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hemodialysis Access Thrombectomy Procedures</title>
        <description>Evaluate the reduction of hemodialysis access thrombectomy procedures</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surveillance Group</title>
            <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group will receive standard monitoring (standard care).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hemodialysis Access Thrombectomy Procedures</title>
          <description>Evaluate the reduction of hemodialysis access thrombectomy procedures</description>
          <units>Procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Hemodialysis Access Angiogram and Angioplasty Procedures</title>
        <description>Evaluate the reduction of hemodialysis access angiogram and angioplasty procedures</description>
        <time_frame>Up to 24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Surveillance Group</title>
            <description>Monthly blood flow surveillance by ultrasound dilution technique and standard of care.&#xD;
Transonic: Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).&#xD;
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines&#xD;
Recirculation, access flow will be performed according to HD03 Manual.&#xD;
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>Control group will receive standard monitoring (standard care).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Hemodialysis Access Angiogram and Angioplasty Procedures</title>
          <description>Evaluate the reduction of hemodialysis access angiogram and angioplasty procedures</description>
          <units>Procedures</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227"/>
                    <measurement group_id="O2" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Surveillance Group</title>
          <description>Monthly standard of care and blood flow surveillance for the duration of the study</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Monthly standard of care for the duration of the study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="207"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study did not achieve targeted numbers for enrollment.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Loay Salman, MD</name_or_title>
      <organization>Albany Medical College</organization>
      <phone>518-262-5176</phone>
      <email>SalmanL@amc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

